IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

Aggregated presentation by day and by market

  

Purchases of own shares from July 15th to 19th, 2024
       
Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 15/07/2024 FR0010259150 4 700 111,6159 XPAR
IPSEN 549300M6SGDPB4Z94P11 15/07/2024 FR0010259150 1 140 111,5494 CEUX
IPSEN 549300M6SGDPB4Z94P11 15/07/2024 FR0010259150 160 111,4563 TQEX
IPSEN 549300M6SGDPB4Z94P11 16/07/2024 FR0010259150 6 781 110,2944 XPAR
IPSEN 549300M6SGDPB4Z94P11 16/07/2024 FR0010259150 3 419 110,3006 CEUX
IPSEN 549300M6SGDPB4Z94P11 16/07/2024 FR0010259150 400 110,2250 TQEX
IPSEN 549300M6SGDPB4Z94P11 16/07/2024 FR0010259150 700 110,1571 AQEU
IPSEN 549300M6SGDPB4Z94P11 17/07/2024 FR0010259150 3 440 110,5364 XPAR
IPSEN 549300M6SGDPB4Z94P11 17/07/2024 FR0010259150 1 218 110,2053 CEUX
IPSEN 549300M6SGDPB4Z94P11 17/07/2024 FR0010259150 342 110,3199 TQEX
IPSEN 549300M6SGDPB4Z94P11 19/07/2024 FR0010259150 10 438 110,0276 XPAR
IPSEN 549300M6SGDPB4Z94P11 19/07/2024 FR0010259150 2 954 109,9632 CEUX
IPSEN 549300M6SGDPB4Z94P11 19/07/2024 FR0010259150 180 109,7000 TQEX
IPSEN 549300M6SGDPB4Z94P11 19/07/2024 FR0010259150 100 109,7000 AQEU
      TOTAL 35 972 110,4203  

Attachment



EN
23/07/2024

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

February 27, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

February 27, 2026 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch